Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
KimanTech
AddedFeb 16, 2024
UpdatedJun 18, 2026
KimanTech

KimanTech

KimanTech offers innovative PCR technology with a unique sample transfer and aliquoting system.

HQ
Salt Lake City, UT, US
Founded
2015
Overview
Compare
Fundraising
Employees

KimanTech's core mission is to revolutionize PCR technology through its innovative sample transfer and aliquoting system. The company offers a unique two-step PCR process with consumable-based product containment, aiming to enhance efficiency and accuracy in molecular diagnostics. KimanTech focuses on serving the biotechnology and healthcare markets, providing advanced solutions for laboratories and research institutions.

KimanTech has made significant strides in improving PCR workflows, garnering attention for its cutting-edge technology. The company's impact is evident in its adoption by leading research facilities and healthcare providers. With a commitment to innovation, KimanTech continues to drive advancements in molecular diagnostics, contributing to more reliable and efficient scientific research.

KimanTech - Similar Companies

Fast PCR Diagnostics logo

Fast PCR Diagnostics

Combinati logo

Combinati

Foodsafetypcr logo

Foodsafetypcr

Kryptos Biotechnologies logo

Kryptos Biotechnologies

kryptosbio.com

Thermal Gradient logo

Thermal Gradient

Prompt Diagnostics logo

Prompt Diagnostics

prompt-dx.com

Carmolex logo

Carmolex

KinaSense logo

KinaSense

Nuclein logo

Nuclein

nuclein.com

Q Biotech logo

Q Biotech

q-biotech.com

Chai logo

Chai

chaibio.com

GMJ Technologies logo

GMJ Technologies

gmjtechs.com

DPX Technologies logo

DPX Technologies

Kantum Pharma logo

Kantum Pharma

Kineolabs logo

Kineolabs

kineolabs.com

KimanTech - Quick Facts

Who are KimanTech's competitors?

Companies similar to KimanTech include Fast PCR Diagnostics, Combinati, Foodsafetypcr and Kryptos Biotechnologies.

When was KimanTech founded?

KimanTech was founded in 2015.

Where is KimanTech's headquarters located?

KimanTech's headquarters is located in Salt Lake City, UT, US.

When was KimanTech's last funding round?

KimanTech's most recent funding round was for $1.5M (USD) in January 2018.

How much has KimanTech raised to-date?

As of Jan 26, 2018, KimanTech has raised a total of $1.5M (USD).

How many employees does KimanTech have?

KimanTech has 5 employees as of Feb 5, 2024.

KimanTech - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Aliquoting
  • PCR
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software